Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
These rates are driven in large part by hepatitis B and C.
Some countries, such as Australia and the United Kingdom, permit people to import generic drugs for personal use.
Their aim is to help remove existing barriers to the production and distribution of generic HCV treatment around the world.
Treatment access advocates warn the move could drastically limit the availability of generic hepatitis C treatment around the world.
Chinese health authorities have yet to approve new HCV treatments, fueling a medical tourism industry worth up to $50 billion.
Lawyers argue that the formula for sofosbuvir was based on “old science” and that the patent should be rejected.
While traveling in India, HepCBC board member and volunteer Cheryl Reitz, confronts her beliefs about generics, and shares her new-found knowl...
The Indian company has become the first drug maker in the country to receive approval to manufacture daclatasvir as a treatment for...
Reporters lauded his treatment advocacy work as ’straight from the script of Dallas Buyers Club.’
Did I sound a bit angry in my last post?
That’s because I was.
The Legality of Importing Medicines into the USA for personal use.
My friends from India recently successfully completed a “worst case scenario” delivery of a three month treatment
Well only two weeks to go until the end of my treatment. I guess it is time for a review of the last ten weeks.
There are seven licensed manufacturers of Sofosbuvir in India, they can produce as much Sofosbuvir and sell it in at least 100 countries
I get an email almost every day now from a Hep C sufferer in the UK who can not get a prescription for Indian generics from their doctor.
If you have been reading this blog for a while you will know that part of what I am doing is helping people to access affordable Hep C meds
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.